New lupus drug CC312 enters first human safety trial

NCT ID NCT07177911

Recruiting now Disease control Sponsor: CytoCares Inc Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-stage study tests a new drug, CC312, in 32 adults with moderate-to-severe systemic lupus erythematosus (SLE). Participants receive either CC312 or a placebo intravenously to check for safety, side effects, and how the drug moves through the body. The goal is to see if CC312 is safe enough to study further as a potential treatment for lupus.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CC312 (a drug given intravenously)
What this could lead to: If this early trial shows CC312 is safe and hints at effectiveness, it could point toward a new treatment option for people with moderate-to-severe lupus.
What could go wrong: This is a very early Phase 1 study with only 32 participants, so it is primarily checking safety, not whether the drug works. Many drugs fail at this stage, and side effects or lack of benefit are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SLE - SYSTEMIC LUPUS ERYTHEMATOSUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SLE - SYSTEMIC LUPUS ERYTHEMATOSUS

Contacts and locations

Locations

West China Hospital, Sichuan University
RECRUITING

Chengdu, Sichuan, 610041, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.